Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 17, 2018. The document serves as a transaction notification regarding a specific insider trading event rather than a comprehensive financial report.
Key Financial Metrics
The filing does not provide aggregate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to a specific transaction:
- Instrument: American Depositary Shares (ADSs), ISIN: US37733W1053.
- Transaction Price: $41.75 per ADS.
- Transaction Volume: 26 ADSs.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely discloses an acquisition of ADSs by a Person Discharging Managerial Responsibilities (PDMR).
Management Commentary and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. The transaction was an acquisition of ADSs following the re-investment of dividends paid on July 12, 2018, to shares held in the Deferred Annual Bonus Plan Post-Tax by Mr. B McNamara, CEO of GSK Consumer Healthcare.
Investor Verification Points
- Verify the identity of the insider: Mr. B McNamara, CEO of GSK Consumer Healthcare.
- Confirm the transaction nature: Acquisition via dividend re-investment plan.
- Note the transaction date: July 12, 2018, executed on the New York Stock Exchange (XNYS).
- Recognize that this filing does not contain quarterly or annual financial performance data.